QINLOCK

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Estonia, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Poland, UK.

Active ingredients

The drug QINLOCK contains one active pharmaceutical ingredient (API):

1	Ripretinib UNII 9XW757O13D - RIPRETINIB
	Ripretinib is a novel tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase and PDGFRA kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.
	Read more about Ripretinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
QINLOCK Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
QINLOCK Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX19		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX19

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02500833
EE	Ravimiamet	1867743, 1867754
FR	Base de données publique des médicaments	67629484
HK	Department of Health Drug Office	67004
IL	מִשְׂרַד הַבְּרִיאוּת	9032
IT	Agenzia del Farmaco	049792017, 049792029
LT	Valstybinė vaistų kontrolės tarnyba	1093697, 1093698
PL	Rejestru Produktów Leczniczych	100462443
US	FDA, National Drug Code	73207-101